Literature DB >> 31670972

The receptor-receptor interaction between mGluR1 receptor and NMDA receptor: a potential therapeutic target for protection against ischemic stroke.

Terence K Y Lai1,2, Dongxu Zhai1, Ping Su1, Anlong Jiang1,2, Jay Boychuk1,2, Fang Liu1,2,3,4.   

Abstract

Ischemic stroke is one of the leading causes of long-term disability worldwide. It arises when the blood flow to the brain is severely impaired, causing brain infarction. The current therapies for ischemic stroke are tissue plasminogen activator and mechanical thrombectomy, which re-establishes blood circulation to the brain but offers no neuroprotective effects. Excitotoxicity, particularly through the N-methyl-d-aspartate receptor (NMDAR), has been heavily implicated in the pathophysiology of brain infarction resulting from ischemic stroke. Here we investigated the interaction between NMDAR and metabotropic glutamate receptor 1 (mGluR1) as a novel target to develop potential neuroprotective agents for ischemic stroke. Through coimmunoprecipitation and affinity binding assay, we revealed that the interaction is mediated through 2 distinct sites on the mGluR1 C terminus. We then found that the disruption of mGluR1-GluN2A subunit of NMDAR (GluN2A) protected the primary mouse hippocampal neurons against NMDAR-mediated excitotoxicity and reversed the NMDAR-mediated regulation of ERK1/2 in rat hippocampal slices. The same protection was also observed in an animal model of ischemic stroke, alleviating brain infarction and yielding better motor recovery. These findings confirmed the existence of a receptor-receptor interaction between NMDAR and mGluR1, implicating this interconnection as a potential treatment target site for ischemic stroke.-Lai, T. K. Y., Zhai, D. Su, P., Jiang, A., Boychuk, J., Liu, F. The receptor-receptor interaction between mGluR1 receptor and NMDA receptor: a potential therapeutic target for protection against ischemic stroke.

Entities:  

Keywords:  excitotoxicity; glutamate; peptide treatment; tMCAO

Mesh:

Substances:

Year:  2019        PMID: 31670972     DOI: 10.1096/fj.201900417R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  8 in total

Review 1.  Progresses in GluN2A-containing NMDA Receptors and their Selective Regulators.

Authors:  Menghan Niu; Xin Yang; Yuanyuan Li; Yanping Sun; Long Wang; Jing Ha; Yinghua Xie; Zibin Gao; Changzheng Tian; Le Wang; Yongjun Sun
Journal:  Cell Mol Neurobiol       Date:  2022-01-03       Impact factor: 5.046

Review 2.  Regulation of membrane NMDA receptors by dynamics and protein interactions.

Authors:  Mar Petit-Pedrol; Laurent Groc
Journal:  J Cell Biol       Date:  2021-01-04       Impact factor: 10.539

3.  The integrative role of G protein-coupled receptor heterocomplexes in Parkinson's disease.

Authors:  Dasiel O Borroto-Escuela; Kjell Fuxe
Journal:  Neural Regen Res       Date:  2022-10       Impact factor: 5.135

4.  Development of a novel peptide to prevent entry of SARS-CoV-2 into lung and olfactory bulb cells of hACE2 expressing mice.

Authors:  Ping Su; Dongxu Zhai; Albert H C Wong; Fang Liu
Journal:  Mol Brain       Date:  2022-08-09       Impact factor: 4.399

Review 5.  Insights on the Functional Interaction between Group 1 Metabotropic Glutamate Receptors (mGluRI) and ErbB Receptors.

Authors:  Ada Ledonne; Nicola B Mercuri
Journal:  Int J Mol Sci       Date:  2020-10-24       Impact factor: 5.923

Review 6.  Excitotoxicity: Still Hammering the Ischemic Brain in 2020.

Authors:  Dennis W Choi
Journal:  Front Neurosci       Date:  2020-10-26       Impact factor: 4.677

Review 7.  Monocyte Transmodulation: The Next Novel Therapeutic Approach in Overcoming Ischemic Stroke?

Authors:  Joohyun Park; Ji Young Chang; Jong Youl Kim; Jong Eun Lee
Journal:  Front Neurol       Date:  2020-10-22       Impact factor: 4.003

8.  Impairments of Long-Term Synaptic Plasticity in the Hippocampus of Young Rats during the Latent Phase of the Lithium-Pilocarpine Model of Temporal Lobe Epilepsy.

Authors:  Tatyana Y Postnikova; Georgy P Diespirov; Dmitry V Amakhin; Elizaveta N Vylekzhanina; Elena B Soboleva; Aleksey V Zaitsev
Journal:  Int J Mol Sci       Date:  2021-12-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.